Therapeutic targets in African-American youth with type 2 diabetes

National Institute Of Diabetes And Digestive And Kidney Diseases

Investigators

Linked publications, trials & patents

Abstract

This is a 3-month randomized trial in youth with type 2 diabetes with 2 intervention arms (metformin alone and metformin and liraglutide). This project successfully screened 39 individuals, enrolled 24 and completed study on 22 participants to meet study primary outcomes. The study was closed to recruitment in Spring 2023 and data analysis completed. Abstracts of primary study findings were presented at national meetings American Diabetes Association Scientific Sessions 2023 and International Society for Pediatric and Adolescent Diabetes 2022. The primary data support improved glycemia and -cell function in youth on short-term combination therapy with metformin and liraglutide independent of changes in new glucose produced by the liver. Metformin was ineffective alone or in combination with liraglutide for lower rates of new glucose produced by the liver and further research is needed to explore therapeutics that will target this early pathological feature. The manuscript has been completed and is being reviewed at a high impact endocrinology journal. Secondary analyses of secondary and exploratory outcomes are underway. We have also generated pilot data that will help decipher the metabolic (including lipoprotein), microbial, pharmacogenetic, and pharmacokinetic factors associated with metformin response in youth-onset type 2 diabetes. The secondary findings on the role of metformin concentrations in assessing adherence and glycemia will be presented at national conference ObesityWeek in October 2023. We will also present findings of greater remnant triglycerides and cholesterol concentrations in youth-onset type 2 diabetes at the American Heart Association Conference November 2024. Ongoing analyses and collaborations are underway with NIH CC Pharmacokinetics Lab, Dr. Hariom Yadav (University of South Florida), Dr. Amy Bentley (NHGRI).